Can Trelegy Cause Urinary Retention?
Yes, Trelegy (fluticasone furoate/umeclidinium bromide/vilanterol) can cause urinary retention and should be used with caution in patients at risk for this condition.
Mechanism and Risk
The urinary retention risk stems specifically from the umeclidinium component, which is an anticholinergic (long-acting muscarinic antagonist). Anticholinergic medications block muscarinic receptors in the bladder detrusor muscle and can impair bladder emptying 1.
FDA-Labeled Warning
The FDA drug label explicitly warns about urinary retention as a serious side effect 1. Patients who take Trelegy may develop new or worse urinary retention, with symptoms including:
- Difficulty urinating
- Painful urination
- Urinating frequently
- Urination in a weak stream or drips
If these symptoms develop, patients should stop taking Trelegy and contact their healthcare provider immediately before taking another dose 1.
High-Risk Populations
Trelegy should be used with particular caution in patients with 1:
- Prostatic hyperplasia (BPH) - The most common risk factor
- Bladder-neck obstruction
- Pre-existing urinary retention
These patients have baseline impairment of bladder emptying, and the anticholinergic effect of umeclidinium can precipitate acute urinary retention requiring catheterization.
Clinical Context
While urinary retention was reported as a serious adverse drug reaction in real-world surveillance (1 patient out of 286 in Japanese post-marketing data) 2, the overall incidence appears relatively low. However, the consequences of acute urinary retention can be severe, requiring emergency catheterization and potentially leading to bladder damage if not promptly addressed.
Practical Management
Before prescribing Trelegy:
- Screen for urinary symptoms and history of retention
- Assess for BPH in male patients (digital rectal exam, symptom assessment)
- Counsel patients on warning signs of urinary retention
- Consider alternative therapies (LABA/LAMA without anticholinergic, or ICS/LABA combinations) in high-risk patients
The anticholinergic class effect is well-established 3, and elderly patients with multiple medications are at particularly elevated risk due to cumulative anticholinergic burden.